Context Therapeutics (CNTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CNTX Context Therapeutics

Watchlist

1.8200
-0.1000-5.21%

Trading Oct 7 14:27 ET

136.50MMarket Cap-1895P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Context Networks and Aristocrat Technologies Partner on API Agreement to Enhance Player Engagement and Drive New Revenue for Gaming Operators
PR NewswireOct 3 08:12 ET
Context Therapeutics Management to Meet With Piper Sandler
TipRanksSep 26 06:51 ET
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsSep 24 14:32 ET · Ratings
Buy Rating Issued for Context Therapeutics on CT-202's Innovative TCE Approach and Market Potential
TipRanksSep 23 11:35 ET · Ratings
BioAtla Licenses Cancer Drug Candidate to Context Therapeutics
InvestingSep 23 07:38 ET
Context Therapeutics Secures Global Rights to Develop and Commercialize BioAtla's Cancer Therapy BA3362
BenzingaSep 23 07:34 ET

Comments

Wonderful Day Mooooo

Sep 27 10:06

keep falling...

$Context Therapeutics (CNTX.US)$

Clintzilla

Sep 23 07:00

$Context Therapeutics (CNTX.US)$ delay in market reaction or institutions own a buttload, if doesnt move all day, look for a push after 3:30 or in a few days

Jaguar8

Sep 23 06:31

NEWS

$Context Therapeutics (CNTX.US)$
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
BioAtla and Context Therapeutics have entered into an exclusive worldwide license agreement for the development and commercialization of BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody. Key points include:
1. Context obtains exclusive rights to BA3362
2. BioAtla to receive $15.0 million in upfront and ...

Wonderful Day Mooooo

Sep 6 09:30

BUY!!

$Context Therapeutics (CNTX.US)$

Jaguar8

Jul 10 06:30

NEWS

$Context Therapeutics (CNTX.US)$
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Context Therapeutics, a biopharmaceutical company specializing in solid tumor treatments, has acquired CT-95, a potentially first-in-class mesothelin x CD3 bispecific antibody from Link Immunotherapeutics. This acquisition, announced on July 10, 2024, aligns with Context’s strategy to expand its pipeline of T cell engager assets. CT-95 has already received Investigational New Drug (IND) clearance...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

CNTX Context Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target